Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

CONCLUSION: The AE profile for cladribine tablets 3.5 mg/kg as a monotherapy has been well-characterized in a pooled population of patients from early to more advanced relapsing MS. There was no increased risk for infections in general except for a higher incidence of herpes zoster. Lymphopenia was amongst the most frequently observed TEAEs that occurred at a higher incidence with cladribine relative to placebo. There was also no increase in malignancy rates for cladribine relative to placebo.
PMID: 30885374 [PubMed - in process]

Source: Herpes - March 20, 2019 Category: Infectious Diseases Authors: Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E Tags: Mult Scler Relat Disord Source Type: research